M. Belker

发表

A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.

V. Devita, B. Burtness, J. Marsh, 2000, Cancer journal.